Funding profile · AI drug development

Atlas Discovery

No Form D, no federal grant and no priced round on record. The only documented investment is the Y Combinator standard deal, and the only commercial figures are the company’s own.

$500KY Combinator standard deal, the published terms for every accepted company
$0Federal grants and SEC Form D offerings on record as of Sep 23, 2026
6 figuresContracted revenue, company-stated, counterparty not named
8 figuresLetter of intent with an AI lab, company-stated, not signed revenue

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2026 Y Combinator, Summer 2026 $500,000 on YC published terms; not separately disclosed for this company Y Combinator YC data
To Sep 2026 Priced round None reported None named Not found
To Sep 2026 Regulation D offering No Form D on file Not applicable SEC EDGAR
To Sep 2026 Non dilutive federal funding None found NIH, NSF Not found

What the filings show

No Form D on file · searched Sep 23, 2026

Issuer search
EDGAR company search for Atlas Discovery returns no matching companies
Form D count
0
Related vehicles
No SPV or fund naming the company found in EDGAR
Federal awards
No NIH or NSF award to this company
Reading
A company can sell SAFEs under Section 4(a)(2) and file nothing, so an empty EDGAR is not evidence that no money moved

Reading the filings

  1. The only documented capital is the accelerator’s.Y Combinator publishes its terms: $500,000 per accepted company, of which $125,000 converts to a fixed 7% on a post money SAFE and $375,000 sits on an uncapped MFN SAFE. Atlas is listed in the Summer 2026 batch, so those terms apply, but no filing confirms the amount for this company.
  2. An empty EDGAR is normal at three months old.Form D is due within 15 days of the first sale in a Regulation D offering. A company funded on SAFEs sold under Section 4(a)(2) files nothing at all. Zero filings is expected here, and it also means there is no third party record of who owns what.
  3. The revenue is small and the letter of intent is large.Six figures of contracted revenue against an eight figure LOI is a ratio of roughly 1 to 100. RuntimeWire marked the LOI down for that reason and still ranked the company, writing that “Atlas’s eight-figure LOI gets attention because there is contracted revenue and biological work happening around it.”
  4. There is no non dilutive money.Companies at this stage in drug discovery often carry an NIH or NSF SBIR award, which brings an outside scientific review with it. Searches of NIH RePORTER and NSF on September 23, 2026 returned nothing, so every dollar so far appears to be accelerator, investor or customer money.
  5. No board can be read from the record.With no Form D there are no related persons to list. The YC profile shows a team of 3 and names Ankit Gupta as primary partner; Gupta co-founded Reverie Labs, acquired by Ginkgo Bioworks in 2024.

Commercial signals

Signal Detail Source type
Contracted revenue Six figures. Customer not named, contract term not disclosed. Company-stated
Letter of intent Eight figures with an unnamed AI lab, for data. An LOI is not a signed contract. Company-stated
Pilot partners Three rare disease foundations testing drugs surfaced by the company’s agents. One is named: Alliance to Cure Cavernous Malformation, which says preclinical testing is beginning. Partner-stated
Published research Two bioRxiv preprints, Feb and Jun 2026, plus released code listed as ICML GenBio 2026. Public record
Regulatory assets None. No FDA record, no registered clinical trial, no owned compound disclosed. Public record

What to watch

  • A first Form D, due within 15 days of the first sale in a Regulation D offering.
  • Whether the eight figure letter of intent converts, and whether the counterparty is named.
  • A priced round after Demo Day, which would set the terms on which the YC MFN SAFE converts.
  • Any NIH or NSF award, which would add an outside review of the science to a record that is currently all self reported.
  • Whether the named foundation partnership produces a preclinical result, the first outcome not scored by the company.

The Atlas Discovery story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • CellType: Also in Drug Discovery and Delivery. A two person Yale spinout that translates single cell biology into a language large models can learn, and is using that model to steer a real cancer drug's next act
  • Harmonic Discovery: Also in Drug Discovery and Delivery. A New York company using machine learning to design kinase drugs that engage several targets on purpose while avoiding the ones that cause harm
  • Verge Genomics: Also in Drug Discovery and Delivery. The first company to carry a drug from an AI platform into ALS patients
  • Parallel Bio: Also in Drug Discovery and Delivery. Miniature human lymph nodes, grown from donated tissue and run side by side across hundreds of donors, used to test drugs and vaccines before anyone takes them

Sources

  1. Public recordEDGAR company search for Atlas Discovery, no matching companiesSEC · Sep 23, 2026
  2. Public recordNIH RePORTER and NSF award searches, no matching awardsAccessed Sep 23, 2026
  3. Public recordThe Y Combinator standard dealY Combinator · Accessed Sep 23, 2026
  4. Public recordDiscrete Diffusion for Single-Cell Gene Expression Modeling, and the June 2026 companion preprintbioRxiv · Feb and Jun 2026
  5. IndependentYC S26’s top decile: the 24 companies RuntimeWire would call firstRuntimeWire · Sep 11, 2026
  6. IndependentAtlas Discovery launches AI models to predict patient response in clinical trialsRuntimeWire, Ryan Merket · Jul 27, 2026
  7. IndependentWhat Y Combinator’s September 2026 Demo Day reveals, noting no priced rounds disclosed beyond the acceleratorEnterprise AI Weekly · Sep 11, 2026
  8. CompanyAtlas Discovery: AI-native pharma company, launch post and YC profileY Combinator · Jul 24, 2026
  9. PartnerAlliance to Cure Cavernous Malformation partnership announcementLinkedIn · Aug 2, 2026

Compiled from SEC, NIH, NSF and other public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; no such notice exists for this company, and companies that sell securities under Section 4(a)(2) file none. Healthcare Venture Capital Fund holds no position in Atlas Discovery. This page is not an offer to sell or a recommendation to buy any security.